Cozaar (
Losartan Carboxylic) first listed in 1994 , is now in 93 countries have been approved for use for the treatment of hypertension . Hyzaar has also including the U.S., 74 countries have been approved for use .
Merck currently apply in some countries outside the United States Cozaar treatment of heart failure indications. And have been registered in 12 countries for the treatment of those who are no longer suitable for the application of angiotensin -converting enzyme inhibitor (ACEI) therapy.
Cozaar and Hyzaar are AIIA class of drugs most prescribed drugs in the world, sales of anti-hypertensive drugs qualifying third . Since the advent of the drug , there have been more than 10 million patients who have taken Cozaar and Hyzaar . As these drugs Cozaar most widely studied drugs , there are more than 4,000 scientific papers published . Cozaar and Hyzaar are developed by Merck .
In order to assess the therapeutic effect of Cozaar , especially in improving hypertension, heart failure and recent heart attack survival rates , reduce morbidity , it has already launched a series of large-scale endpoint studies, including LIFE ( Cozaar treatment of hypertension survival Study ) and OPTIMAAL ( Cozaar after myocardial infarction study ) .
For Cozaar Kidney Protection Study (RENAAL) has published the annual meeting of American Society of Hypertension . This new landmark study achieved its primary goal , the first time demonstrated Cozaar for hypertension associated with type 2 diabetic nephropathy patients with renal protection . Cozaar group in patients with end-stage renal disease risk reduction of 28 %, usually these patients require dialysis and kidney transplant to maintain life .
More about:
Losartan Carboxylic Acid suppliers
From:
Natural herbal extracts
